Clinical Research


If you think you may qualify for one of these studies, please contact Neurology Research Partners at (303) 724-4644 or



COMIRB #Title (Please click on the title to see approved advertisement)Principal InvestigatorEligibility and InformationAdvertisement
21-3126The Evaluation Of Immune Responses To Sars-Cov-2 mRNA Vaccines In Multiple Sclerosis Patients On OcrelizumabAmanda Piquet, MDClinical TrialsSee Advertisement
12-0968Rocky Mountain Multiple Sclerosis Center (RMMSC) Biorepository for the Study of Neuroimmunological DisordersEnrique Alvarez, MD, PhDClinical TrialsN/A
18-1633Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS)Enrique Alvarez, MD, PhDClinical TrialsN/A
17-1884Risk Factors in Early Multiple Sclerosis (RISE-MS)John Corboy, MDClinical TrialsSee Advertisement
19-0393Detection and Risk in Early MS (DREAMS)Teri Schreiner, MD, MPHN/ASee Advertisement
09-0952Rocky Mountain MS Center Tissue BankJohn Corboy, MDClinical TrialsN/A
19-1600An Observational Study Of Ocrelizumab Treated Patients With Multiple Sclerosis To Determine The Incidence And Mortality Rates Of Breast Cancer And All Malignancies Amanda Piquet, MDN/ASee Advertisement
20-1000Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)Enrique Alvarez, MD, PhDClinical TrialsN/A
16-0156Natalizumab for Prevention of Post-Partum Relapses in Patients with Multiple SclerosisTeri Schreiner, MD, MPHClinical TrialsN/A
Evaluating the Feasibility of Pandemic Forward, Telehealth Based Home Based Infusions for Ocrelizumab Users: Measuring Patient Experiences and Safety Outcomes
Tim Vollmer, MD
Clinical TrialsSee Advertisement
19-1040A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Ocrelizumab Administration in Patients with Multiple SclerosisAmanda Piquet, MDClinical TrialsN/A
19-2525Lipoic Acid for the Treatment of Progressive Multiple SclerosisRobert Gross, MDClinical TrialsN/A

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients with Relapsing-Remitting Multiple Sclerosis

Tim Vollmer, MDClinical TrialsSee Advertisement
20-0705A Single-Arm, Prospective, Multicentre, Open-Label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients with Relapsing Multiple Sclerosis Transitioning from Dimethyl Fumarate or Fingolimod TherapyEnrique Alvarez, MD, PhDClinical TrialsN/A
20-0454A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis Enrique Alvarez, MD, PhDClinical TrialsN/A
20-0695Low Load Resistance Training Using Blood Flow Restriction for People with Multiple Sclerosis with Marked Mobility RestrictionMark Manago, DPT, PhD, PT, NCSClinical TrialsSee Advertisement
Comparative Effectiveness of an Exercise Intervention Delivered via Telerehabilitation and Conventional Mode of Delivery
Jeffrey Hebert, PT, PhD
Clinical Trials
See Advertisement
20-1527Proximal Resistance Training to Improve Walking Capacity and Physical Activity in People with Multiple SclerosisMark Manago, DPT, PhD, PT, NCSClinical TrialsSee Advertisement